Sanofi and Exscientia have entered a research partnership and licence agreement for the development of up to 15 new small-molecule medicines across oncology and immunology.
The precision-engineered medicines will be developed using an end-to-end artificial intelligence (AI)-driven platform of Exscientia using real samples from patients.
The alliance will identify and choose target projects using the tailored medicine platform of Exscientia.
By incorporating initial human tissue samples into an early target and drug discovery research, this platform facilities a ‘patient-first’ approach.
This method could aid researchers at Exscientia to combine patient, ailment and clinically significant data into decisions on prospective new therapy candidates earlier in the process of drug development.
Sanofi will be responsible for preclinical and clinical development, production and marketing of the candidates.
Under the deal, Exscientia is entitled to receive a $100m upfront payment in cash from Sanofi.
Sanofi will also make aggregate payments of up to nearly $5.2bn to Exscientia on meeting research, translational, clinical development, regulatory and commercial milestones in the future.
Leave a Reply